Ventyx Biosciences News

Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer

TipRanksMay 10 19:58

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)

TipRanksMay 10 19:30

Ventyx Biosciences: A Prudent Hold Amidst Promising Drug Potential and Market Uncertainties

TipRanksMay 10 18:28

Buy Rating for Ventyx Biosciences Based on Clinical and Financial Strengths

TipRanksMay 10 17:59

Ventyx Biosciences | 10-Q: Quarterly report

Futu NewsMay 10 04:27 · Announcements

Ventyx Biosciences: Cash, Equivalents and Marketable Securities Expected to Fund Planned Ops Into at Least 2H of 2026 >VTYX

Ventyx Biosciences: Cash, Equivalents and Marketable Securities Expected to Fund Planned Ops Into at Least 2H of 2026 >VTYX

Dow JonesMay 10 04:18

Ventyx Biosciences Q1 2024 GAAP EPS $(0.62) Beats $(0.67) Estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.67) by 7.46 percent.

BenzingaMay 10 04:02

Ventyx Biosciences 1Q Loss $38.6M >VTYX

Ventyx Biosciences 1Q Loss $38.6M >VTYX

Dow JonesMay 10 04:02

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a r

GlobeNewswireMay 3 04:05

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54

Zhitong FinanceMay 2 04:55

Ventyx Biosciences Drops 3%, Stockholders to Sell ~11.17M Shares

Seeking AlphaApr 10 16:06

Ventyx Biosciences CBO Christopher Krueger Steps Down

TipRanksApr 6 05:22

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. Shares of Kura Sushi USA, Inc. (NASDAQ:KRUS) climbed 6% to $110.11 in pre-market trading foll

BenzingaApr 5 20:01

Ventyx Biosciences (VTYX) Gets a Buy From LifeSci Capital

TipRanksApr 1 22:05

Canaccord Genuity Maintains Buy on Ventyx Biosciences, Lowers Price Target to $15

Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences with a Buy and lowers the price target from $16 to $15.

Analyst UpgradesMar 13 22:15

Ventyx Biosciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 77.2% Canaccord Genuity $16 → $15 Maintains Buy 03/12/2024 41.76% Oppenheimer → $12 Upgrades Pe

BenzingaMar 13 22:14

Buy Rating Affirmed for Ventyx Biosciences on Strong Clinical Pipeline and Promising Drug Developments

TipRanksMar 13 19:06

Ventyx Biosciences Shares Rise After Oppenheimer, Wells Fargo Upgrades

Ventyx Biosciences (VTYX) shares were up about 5% in recent Tuesday trading after Oppenheimer and Wells Fargo upgraded their ratings for the clinical-stage biopharmaceutical company. Oppenheimer upgra

MT NewswiresMar 13 02:33

Ventyx Rebounds as Oppenheimer Upgrades After Pipeline Updates

Seeking AlphaMar 12 20:27

Buy Rating Affirmed: Ventyx Biosciences' Promising Clinical Advances and Strategic Position for Market Opportunities

TipRanksMar 12 19:16